Doug L. Hayden, MA
- 2Articles
- 6.3KReads1
- 2005–2006Active
- 14Collaborators
1 Read counts for articles published before 2020 may include some non-human traffic.
About
Doug L. Hayden, MA, has contributed to research on metabolic disorders in the context of schizophrenia and schizoaffective disorders. His work includes studies on glucose metabolism in patients treated with antipsychotic medications such as olanzapine and quetiapine, as well as investigations into the long-term cardiovascular risks associated with clozapine treatment. Hayden has collaborated with co-authors including A. Eden Evins and Donald C. Goff and published in Psychiatrist.com between 2005 and 2006.
Publications
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
